HYALGAN 20 MG / 2 ML ( SODIUM HYALURONATE ) INTRA-ARTICULAR PRE-FILLED SYRINGE

What is HYALGAN®?
HYALGAN® is a solution that contains a natural substance called hyaluronate. Hyaluronate is normally found in the fluid that lubricates and cushions your knee joint. HYALGAN® is injected into your knee to relieve pain due to osteoarthritis.

HYALGAN® is a treatment option for people who do not get adequate pain relief from simple painkillers (like Tylenol® or Advil®) or from exercise and physical therapy. HYALGAN® injections can be used in addition to prescription pain relievers.

Hyalgan box and needle:

• HYALGAN® is injected directly into your knee by your health care provider.
• HYALGAN® is a 5-injection regimen given at weekly intervals that provides long-lasting pain relief for up to 6 months

* Some patients get benefits with 3 injections given at weekly intervals.

* Some patients may experience benefit with 3 HYALGAN® injections given at weekly intervals. This has been noted in published literature on patients receiving 3 injections who were followed for 60 days.

Individual results may vary but HYALGAN® has shown to relieve knee pain for up to 6 months.

Indication
HYALGAN® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and to simple analgesics, eg, acetaminophen.

Important Safety Information
HYALGAN is contraindicated in patients with known hypersensitivity to hyaluronate preparations or in cases of present infections or skin diseases in the area of the injection site. Use caution when injecting HYALGAN into patients who are allergic to avian proteins, feathers, and egg products.

The safety and effectiveness of HYALGAN has not been established in children or in pregnant or lactating women, for use in other joints or for concomitant use with other injectables. It is unknown whether HYALGAN® is excreted in human milk. The effectiveness of a single treatment cycle of less than 3 injections has not been established.

Transient increases in inflammation in the injected knee following HYALGAN injection have been reported in some patients with inflammatory arthritis and should not be injected if objective signs of inflammation are present. Transient pain and/or swelling of the injected joint may occur after intra-articular injection of HYALGAN®. Anaphylactoid and allergic reactions have been reported with the use of this product.

In the US clinical trial, adverse events included injection-site pain, gastrointestinal complaints, headache, local ecchymosis (bruising) and rash, local joint pain and swelling, and local pruritus (itching). In other clinical studies, the frequency and severity of adverse events occurring during repeat treatment cycles did not increase over that reported for a treatment cycle.

Write a review